PMV Pharmaceuticals, Inc. (PMVP) Form 8-K — May 12, 2026
PMV Pharmaceuticals, Inc. reported its financial results for the first quarter ended March 31, 2026, with a cash position of $93.5 million, a net loss of $18 million, and EPS of -$0.34. The company's cash runway is expected to last until the end of the second quarter of 2027. The U.S.
Key figures
- Eps
- -0.34
- Eps Beat
- 0
- Revenue
- 0
- Net Income
- -18,038,000
- Total Debt
- 8,595,000
- Debt Amount
- 0
- Revenue Yoy
- 0
- Total Assets
- 96,562,000
- Cash Position
- 93.5 million
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 53,331,766
- Rezatapopt orr
- 46% (34/74 patients)
- Rezatapopt nda submission
- Planned for first quarter of 2027
- Rezatapopt median time to response
- 1.3 months
- Rezatapopt orphan drug designation
- Granted for TP53 Y220C positive ovarian cancer
- Rezatapopt median duration of response
- 8.2 months
Price after filing
1 day: -9.2%7 days: -7.7%30 days: -25.4%
Close on the filing date to close N calendar days later (from $1.42). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.